Changes in the carrying amount of goodwill, by reportable segment, for the years ended December 31, 2024 and 2023 were as follows:


	Automotive			Medical			Total
Balance as of December 31, 2022	$	73,069		$	46,705		$	119,774
Impairment of goodwill		—			(19,509	)		(19,509	)
Currency translation and other		3,627			181			3,808
Balance as of December 31, 2023	$	76,696		$	27,377		$	104,073
Currency translation and other		(3,942	)		(528	)		(4,470	)
Balance as of December 31, 2024	$	72,754		$	26,849		$	99,603

Other intangible assets and accumulated amortization balances as of December 31, 2024 and 2023 were as follows:


	Gross Carrying Value		Accumulated Amortization			Accumulated Impairment			Net Carrying Value
Definite-lived:
Customer relationships	$	109,608	$	(67,787	)	$	(5,477	)	$	36,344
Technology		43,458		(29,976	)		(24	)		13,458
Product development costs		18,019		(17,849	)		—			170
Software development		1,007		(201	)		—			806
Indefinite-lived:
Tradenames		7,003		—			(530	)		6,473
Balance as of December 31, 2024	$	179,095	$	(115,813	)	$	(6,031	)	$	57,251

	Gross Carrying Value		Accumulated Amortization			Accumulated Impairment			Net Carrying Value
Definite-lived:
Customer relationships	$	115,465	$	(67,923	)	$	(5,814	)	$	41,728
Technology		45,861		(29,292	)		(25	)		16,544
Product development costs		19,434		(19,270	)		—			164
Software development		1,007		—			—			1,007
Indefinite-lived:
Tradenames		7,039		—			—			7,039
Balance as of December 31, 2023	$	188,806	$	(116,485	)	$	(5,839	)	$	66,482

During the first quarter of 2024, we recorded a non-cash impairment charge of $530 for one of our Medical tradenames.

As of December 31, 2022, the estimated fair value of the Medical reporting unit exceeded its carrying value by less than 10%. During the second quarter of 2023, the Company’s Medical reporting unit did not perform in-line with forecasted results primarily driven by slower than anticipated revenue growth. As a result, an indicator of impairment was identified and the Company performed an interim quantitative assessment as of June 30, 2023. The results of this quantitative analysis indicated the carrying value of the reporting unit exceeded the fair value of the reporting unit, and accordingly an impairment expense was recorded for $19,509. The Company performed its annual assessment of the Medical reporting unit goodwill as of December 31, 2024 and 2023 utilizing quantitative approaches and determined the fair value of the Medical reporting unit exceeded its carrying value at each date.

The Company utilized an income approach to estimate the fair value of the reporting unit and a market valuation approach to further support this analysis (level 3). The income approach was based on projected debt-free cash flow that was discounted to the present value using discount factors that considered the timing and risk of cash flows. Fair value was estimated using internally developed forecasts, as well as commercial and discount rate assumptions. The discount rate used was the value-weighted average of our estimated cost of equity and of debt (“cost of capital”) derived using both known and estimated customary market metrics. Our weighted average cost of capital includes a company specific risk premium to address the risks associated with achieving the projected revenue and profitability growth rates. Other significant assumptions included terminal value growth rates and terminal value margin rates. Our ability to realize the future cash flows used in our calculations is affected by factors such as the success of strategic initiatives, changes in economic conditions, changes in our operating performance and changes in our business strategies. To further support the fair value estimate determined by the income approach, the Company utilized a market valuation approach to estimate the fair value of the Medical reporting unit. The market approach considered historical and anticipated financial metrics of the Medical reporting unit and applied valuation multiples based on recent observed transactions involving companies similar enough to the Medical reporting unit from which to draw meaningful conclusions.

In addition to annual impairment testing, which is performed in the fourth quarter of each fiscal year, the Company continuously monitors for events and circumstances that could negatively impact the key assumptions used in determining fair value and therefore would require interim impairment testing, including long-term revenue growth projections, profitability, discount rates, recent market valuations from transactions by comparable companies, volatility in the Company's market capitalization, and general industry, market and macroeconomic conditions. We are not presently aware of any other events or circumstances that would require us to revise the carrying value of our goodwill or other intangible assets as of December 31, 2024.

A total of $7,019, $8,290, and $9,018 in other intangible assets were amortized in 2024, 2023 and 2022, respectively.